Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 13/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 12/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.82 |
| ▸ | FLT3 | P36888 | 7/20 | 0.79 |
| ▸ | FLT4 | P35916 | 3/20 | 0.79 |
| ▸ | KIT | P10721 | 1/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.72 |
| ▸ | AURKA | O14965 | 2/20 | 0.71 |
| ▸ | RET | P07949 | 2/20 | 0.71 |
| ▸ | FLT1 | P17948 | 2/20 | 0.71 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.71 |
| ▸ | STK3 | Q13188 | 2/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.71 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.71 |
| ▸ | LATS1 | O95835 | 1/20 | 0.71 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411069 | 1.00 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408521 | 0.93 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408517 | 0.93 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408641 | 0.90 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4408645 | 0.90 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL29435065 | 0.90 | KDR (1.00) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4417271 | 0.87 | KDR (0.77) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL4417269 | 0.87 | KDR (0.77) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL6326835 | 0.87 | KDR (0.77) | KDRFGFR1PDGFRBEGFRFLT3 | |
| SCHEMBL6406432 | 0.87 | KDR (0.76) | KDRFGFR1PDGFRBEGFRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-05 | — | — | US | claimed |
| US-6395734-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2002-05-28 | — | — | US | claimed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6395734-B1 | ANTICANCER AGENTS | SUGEN, INC. | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105151-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | DMPK, PDPK1, PLK2 | KDR 1066/4885FGFR1 930/4885PDGFRB 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.